Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London close: Shares end near session high

Thu, 29th Oct 2009 16:23

London's top stocks closed near its session high on news that the US economy grew faster than expected in the third quarter.Traders loved news that the US economy grew 3.5% annually in the last quarter, more than expected and the fastest rate of increase in two years.Part-nationalised bank Lloyds Banking has confirmed it is contemplating digging an escape tunnel from the government's asset protection scheme.Lloyds said it is in advanced discussions with UK authorities regarding alternatives to entering the state insurance scheme for toxic debt. The lender is considering raising cash via an underwritten rights issue and debt swap. The shares have advanced strongly on the news, dragging fellow part-nationalised lender Royal Bank of Scotland with them, while Barclays was also wanted.Asia-focused bank Standard Chartered also cheered after it said its markets in Asia, Africa and the Middle East are pulling out of the recession quicker than many markets in the West. The group, which notched up record income and profits in the first half of the year, said it continued to make 'good progress' in the third quarter.Royal Dutch Shell remained in the doghouse. In a week in which long time rival BP topped market expectations with its third quarter results, the Anglo-Dutch oil giant's third quarter earnings (on a current cost of supplies (CCS) basis) of $3bn, down from $10.9bn a year ago, failed to enthuse the market.The figures were broadly in line with expectations but upstream earnings disappointed. BG Group, which announced third quarter results yesterday, joins Shell on the slide, as does sector peer Cairn Energy. Production at Cairn's Indian operations continued to rise in the third quarter while the average realised price per barrel of oil equivalent was $51.48.AstraZeneca's third quarter earnings beat market forecasts with a 27% hike in profit at constant exchange rates (CER), prompting the Anglo-Swedish drug giant to lift full-year targets. But the excitement soon petered out and the shares fell.Life assurance group Standard Life saw strong growth in assets in the third quarter as the markets continued their recovery. Assets under management rose by £15.3bn in the third quarter to £136.9bn. Third party assets under management jumped to a record £54.1bn from £47.3bn at the end of June.Elsewhere in the sector, Prudential was better after some positive comment in the papers following yesterday's results. Sales fell 9% during the third quarter. Aviva and Legal & General are also higher.Shares in Kazakhmys recovered from a poor start. The Kazakh miner said it is on track to hit full year targets, even though maintenance work could hit Q4 output. Higher metal prices also had Xstrata, Fresnillo, Anglo American and Antofagasta ahead.Among the mid-caps, CSR posted a fall in profits but said it was seeing strong levels of business now. A change at the top at defence technology firm Qinetiq had been warmly received by the City. Graham Love is being replaced as chief executive officer at Qinetiq by the former chief of banknote printer De La Rue, Leo Quinn.Cash-strapped Yellow Pages directory publisher Yell Group has again extended the deadline for its refinancing. The company, which is looking to restructure £3.8bn of debt, extended the deadline for the third time this week after last night's cut-off passed without success.National Express fell back after calling off talks with suitor Stagecoach. It will now focus on completing an equity fundraising by the end of this year. Stagecoach said it was disappointed.Fellow rail and bus group Arriva said it has continued to trade in line with expectations since August 27 with strong growth in bus operations and a continued good performance from trains.Elsewhere in the sector, Go Ahead said it had seen growth slightly ahead of expectations in its bus and aviation operations over the first quarter and that rail operations were continuing to trade in line with forecasts.The ascent of Evolution continued, after the investment management firm said it expects to beat full year profit forecasts. Sector peer Henderson Group was cold shouldered, however, despite assets under management increasing by 9% to £57.7bn in the third quarter.FTSE 100 - RisersRoyal Bank of Scotland Group (RBS) 43.37p +9.52%Lloyds Banking Group (LLOY) 86.00p +7.50%Xstrata (XTA) 947.00p +7.37%Fresnillo (FRES) 802.00p +6.65%Kazakhmys (KAZ) 1,186.00p +6.56%Anglo American (AAL) 2,300.00p +5.60%SEGRO (SGRO) 363.30p +5.40%Prudential (PRU) 577.50p +4.90%Vedanta Resources (VED) 2,218.00p +4.57%Eurasian Natural Resources (ENRC) 889.00p +4.47%FTSE 100 - FallersRoyal Dutch Shell 'B' (RDSB) 1,813.00p -3.02%Royal Dutch Shell 'A' (RDSA) 1,856.00p -2.88%AstraZeneca (AZN) 2,752.00p -1.33%BAE Systems (BA.) 315.20p -1.22%British American Tobacco (BATS) 1,939.00p -0.92%Shire Plc (SHP) 1,024.00p -0.68%Smith & Nephew (SN.) 543.00p -0.55%Severn Trent (SVT) 954.50p -0.52%Alliance Trust (ATST) 308.60p -0.48%Rentokil Initial (RTO) 105.10p -0.47%
More News
27 Jul 2018 13:14

Friday broker round-up

(Sharecast News) - William Hill: Peel Hunt upgrades to hold with a target price of 305p.

Read more
26 Jul 2018 12:54

Evgen Pharma Expects Final Results From Clinical Trials At End Of Year

LONDON (Alliance News) - Evgen Pharma PLC said Thursday it expects to receive the final read-out from two clinical trials by the end of 2018.The drug development company said at its annual

Read more
25 Jul 2018 14:48

Evgen concludes patient recruitment in STEM breast cancer trial

(Sharecast News) - Clinical-stage drug development company Evgen Pharma has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic breast cancer, it announced on Wednesday.

Read more
25 Jul 2018 13:57

Wednesday broker round-up

(Sharecast News) - Unite Group: Numis downgrades to hold with a target price of 900p.

Read more
25 Jul 2018 13:31

Evgen Pharma Metastatic Breast Cancer Trial Ends Patient Recruitment

LONDON (Alliance News) - Evgen Pharma PLC said Wednesday it has concluded its patient recruitment for its STEM Phase IIa trial of SFX-01 in metastatic breast cancer.Following the favourable

Read more
19 Jul 2018 16:21

UK Shareholder Meetings Calendar - Next 7 Days

Friday 20 JulyHomeserveKCOM GroupMonday 23 JulyEthernity Energy 24

Read more
13 Jun 2018 10:46

Evgen Pharma Annual Loss Narrows As It Continues Phase II Trials

LONDON (Alliance News) - Clinical drug development company Evgen Pharma PLC said Wednesday its annual loss narrowed in line with expectations.Evgen, which focuses on cancer and neurological

Read more
11 Jun 2018 11:33

Evgen STEM Interim Trial Result Show "Signs Of Anti-Tumour Activity"

LONDON (Alliance News) - Evgen Pharma PLC said Monday its STEM trial showed "early signs of anti-tumour activity" in breast cancer patients.STEM is the company's study of in a

Read more
2 May 2018 11:15

Evgen Pharma Gets European Patent For Sulforaphane Stablising Method

LONDON (Alliance News) - Drug development company Evgen Pharma said Wednesday that it has secured a European patent recognising its intellectual property for a method of stabilising sulforaphane,

Read more
20 Mar 2018 13:56

Evgen Pharma Begins Research Partnership With Imperial College London

LONDON (Alliance News) - Drug development company Evgen Pharma PLC has started a new research collaboration with Imperial College London focusing on SFX-01, the company's

Read more
13 Feb 2017 08:21

Evgen Pharma signs service agreement with drug development corsortium

(ShareCast News) - AIM-listed Evgen Pharma has signed a services agreement with a consortium of Cheshire-based drug developments firms for its sulforaphane product. APT Trans, the consortium of drug developers based in the Biohub at Alderley Park, which comprises of Aptus Clinical, Apconix and Seda

Read more
17 Jan 2017 12:35

Richard Moulson to join Evgen Pharma as CFO

(ShareCast News) - Clinical-stage drug development company Evgen Pharma announced the appointment of experienced healthcare executive Richard Moulson as its chief financial officer on Tuesday. The AIM-traded firm said Moulson was joining immediately as CFO-designate for a handover period to 28 Febru

Read more
11 Jan 2017 09:23

Evgen Pharma receives go ahead for haemorrhage drug trial

(ShareCast News) - Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has received a positive interim safety review from the independent Data Safety Monitoring Board (DSMB) for its Phase II double-blind placebo-controlled SAS trial

Read more
11 Jan 2017 09:17

Evgen Pharma Gets Positive Review For SFX-01 Phase II Study

Read more
17 Aug 2016 10:49

Evgen Pharma receives approval for breast cancer study

(ShareCast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that it has received a Clinical Trial Approval from the UK's regulatory agency for the commencement of its Phase II clinical trial of SFX-01 in breast cancer. The AIM-traded firm said patient recruitment w

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.